In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

France Warns Diabetics And Others Against Using Joint Health Supplements

Executive Summary

Diabetics, pregnant women, children, and those with certain food allergies in France should stop taking joint health supplements containing glucosamine and/or chondroitin sulfate due to a risk of adverse events, says national food regulator ANSES. Local supplements industry association Synadiet has insisted the products are safe and cases of adverse reactions rare.

You may also be interested in...



Vitamin D Supplements For Children Present Overdose Risk, Say French Regulators

France's food and drug regulators say children should only be given vitamin D in approved drugs after cases were reported of overdose in infants linked to supplement use.

Glucosamine Supps For Heart Health? Large UK Biobank Study Says Yes

A large-population UK study published in the British Medical Journal has found that habitual use of glucosamine supplements may reduce the risk of cardiovascular disease events, such as 

MHRA set to reclassify glucosamine supplements

High-strength glucosamine food supplements sold in the UK will now be classified as medicines and require a marketing authorisation after the country’s Medicines and Healthcare products Regulatory Agency (MHRA) introduced tighter regulations for such products.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148684

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel